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1. Introduction 
In the last few years the ever-growing interest in the field 
of nucleosides and nucleotides has led to renewed efforts in 
the synthesis of analogues.
1
 Modifications in the sugar 
moiety are one of the most important kind of nucleoside 
derivatives that can lead to promising chemotherapeutic 
agents.
2
 These compounds have attracted much attention as 
potential antiviral and anticancer agents.
3
 Due to their use 
as building-blocks to prepare anti-sense and anti-gene 
oligonucleotides, they also emerge as potential and 
selective inhibitors of gene expresion.
4
 Particularly, amino 
sugar nucleosides are important bioactive molecules,
5
 of 
which puromycin (3’-amino-2’,3’-dideoxyadenosine) is 
one of the most important examples. One of the major 
strategies for the synthesis of sugar-modified nucleosides is 
the modification of the intact nucleosides.
6
 Although there 
has been a growing demand for the development of 
nucleoside-base therapeutics, 3’,5’-diamino-2’,3’,5’-
trideoxynucleosides remains to some extent unexplored 
mainly due to the difficult synthetic accessibility. There is 
very little in the literature concerning the synthesis of such 
nucleosides.
7
  
In our ongoing study to elucidate the effects of amino-
derivatized nucleosides on critical biosynthetic pathways as 
well as their use as monomers for the preparation of 
antisense oligonucleotides, we first reported the synthesis 
of 3’,5’-diamino-3’,5’-dideoxythymidine and 3’,5’-
diamino-2’,3’,5’-trideoxyuridine.8 With these 
considerations in mind, we describe here for the first time 
the preparation of 3’,5’-diamino-2’,3’,5’-trideoxycytidine 
and an efficient alternative synthesis to N-benzoyl-3’,5’-
diamino-2’,3’,5’-trideoxyadenosine. Additionally, we 
perform protonation studies of 3’,5’-diaminonucleoside 
derivatives of 2’-deoxycytidine, 2’-deoxyadenosine, 
thymidine, and 2’-deoxyuridine with the aim of finding the 
ionization constants and the sequence of protonation sites 
on these molecules. 
2. Results and disscusion 
Starting from 2’-deoxyuridine (1) we previously 
synthesized 3’,5’-diazido-2’,3’,5’-trideoxyuridine (2) 
through a simple and efficient three step procedure.
8
 This 
diazido compound was treated
9
 with phosphorus 
oxychloride, 1,2,4-triazole, and triethylamine in acetonitrile 
at room temperature for 1 h to afford the 4-
triazolylpyrimidinone derivative 3 (Scheme 1). Subsequent 
treatment with aqueous ammonia in 1,4-dioxane solution 
give the cytidine derivative 4. Hydrogenation of 4 in EtOH 
in the presence of 10% Pd/C yielded 3’,5’-diamino-
2’,3’,5’-trideoxycytidine (5) with 29% overall yield. 
For the synthesis of N-benzoyl-3’,5’-diamino-2’,3’,5’-
trideoxyadenosine (12), 5’-O-protected adenosine 
derivative 6 (commercially available) was subjected to 
Mitsunobu conditions (Scheme 2). Thus, esterification of 
the hydroxyl group at 3’ position takes place with inversion 
of configuration giving place to ester 7. Methanolysis of the 
p-nitrobenzoate ester and cleavage of the dimethoxytrityl 
group with catalytic amounts of formic acid in CHCl3 
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afforded N-benzoyl-2’-deoxyxyloadenosine (9). Mesylation 
of 9 proved difficult, the 5’-O-mesyl derivative and 
fragments corresponding to the hydrolysis of the glycosidic 
bond being observed when the reaction was carried out 
with 2.2 equivalents of mesyl chloride in pyridine at 0 °C. 
 
Scheme 1. Synthesis of 3’,5’-diamino-2’-deoxycytidine. 
This hydrolysis could be explained by initial protonation of 
the base moiety followed by dissociation of the protonated 
nucleoside to a glycosyl oxocarbenium ion and the free 
purine.
10
  
 
Scheme 2. Synthesis of 3’,5’-diamino-2’-deoxyadenosine N-benzoylated. 
Although the pKa of pyridine (5.29) is greater than the pKa 
of adenine (4.25), it seems that the difference is not enough 
to shift the equilibrium toward the protonation of pyridine. 
For this reason, we carried out the reaction in a medium of 
triethylamine (pKa= 10.75). As the model nucleoside we 
choose N-benzoyl-2’-deoxyadenosine (13, Scheme 3). 
 
Scheme 3. Mesilation reaction with model nucleoside, 2’-deoxyadenosine 
N-benzoylated. 
However, the process was slower than before, and a 
mixture of starting material and 5’-O-mesyl derivative 14 
was obtained (entry 1, Table 1). Next, the reaction was 
carried out with Et3N as base and pyridine as solvent 
(entries 2–5. Table 1). The best result was observed with a 
ratio Et3N:Py 1:4 (v/v), the desired compound 15 being 
isolated in 65% yield after flash chromatography. In 
addition, monomesyl derivative 14 was obtained in 12% 
yield. The use of imidazol (pKa= 7.0) as base gave rise to a 
complex mixture (entry 6, Table 1). However, when the 
process was performed with 10 equivalents of DMAP 
(pKa= 9.7) in pyridine solution and 6 equiv. of MsCl, 3’,5’-
di-O-mesyl nucleoside 15 was achieved exclusively after 2 
h in quantitative yield (entry 7, Table 1). DMAP makes the 
reaction faster and this avoids the hydrolysis of the 
glycosidic bond in solution. 
Table 1. Mesylation Reaction of N-Benzoyl-2’-deoxyadenosine (13). 
entry Base (equiv.) equiv. of 
MsCl 
t (h) 13 
(%)a 
14 
(%)a 
15 
(%)a 
16 
(%)a 
1 Et3N
b 4 13 50 50   
2 Et3N (6) 4 23  70 30  
3 Et3N (1:1 v/v) 6 66  30 30 40 
4 Et3N (1:2 v/v) 6 66  20 40 40 
5 Et3N (1:4 v/v) 6 66  12
c 65c  
6 Imidazol (10) 6 72 complex mixture 
7 DMAP (10) 6 2   99c  
a Calculated by 1H NMR. b As base and solvent. c Isolated yields after 
flash chromatography. 
Extension of this reaction to the xylonucleoside 9 led to the 
formation of di-O-mesyl derivative 10 in 75% yield 
(Scheme 2). Subsequent treatment of 10 with sodium azide 
in DMF solution afforded diazido 11. Hydrogenation of the 
latter in EtOH in the presence of Pd black gave N-benzoyl-
3’,5’-diamino-2’,3’,5’-trideoxyadenosine (12). This 
efficient six-step procedure from readily available starting 
material gave 12 in 29% overall yield. 
Additionally, we report here the protonation behavior of 
both 3’,5’-diamino nucleosides 5 and 12, and the 
previously reported
8
 3’,5’-diamino-3’,5’-dideoxythymidine 
(17) and 3’,5’-diamino-2’,3’,5’-trideoxyuridine (18) 
(Figure 1) using pH-metric measurements and NMR 
spectroscopy. To determine the stepwise protonation sites 
we recorded their 
1
H and 
13
C NMR spectra at different pD 
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values (pD= pH+0.4). As a general rule, when pD is 
decreased, proton atoms in the -position to the protonated 
nitrogen move downfield while -C signals move upfield.11 
 
Figure 1. 3’,5’-Diamino-3’,5’-dideoxythymidine and 3’,5’-diamino-
2’,3’,5’-trideoxyuridine. 
 
  
  
Figure 2. 1H NMR chemical shift of: (a) diamino-dC, 5; (b) N-Bz-diamino-
dA, 12; (c) diamino-T, 17; (d) diamino-dU, 18 as a function of pD. 
For all diaminonucleosides, in the range pD 12-10, no 
appreciable variations in the chemical shifts of 
1
H and 
13
C 
NMR spectra occurred, but between pD 10 and 8 a 
significant downfield of H-5’ and an upfield of C-4’ were 
observed (Figures 2 and 3). The shift of C-4’ can be 
ascribed to protonation at N-5’ or N-3’, but the fact that C-
2’ did not experience a clear shift suggests that the first 
proton binding to the molecule occurs mainly at the amino 
group of the 5’-position. In the pD range 8-5, the most 
significant shifts are shown by H-3’, C-4’, and C-2’, which 
confirms the second protonation to be predominantly at the 
N-3’ position.  
An additional protonation is expected for 3’,5’-diamino-2’-
deoxycytidine (5) due to the presence of an extra amino 
group on the base. Nucleoside 5 lacks a hydrogen in the -
position to this amino group. However, a downfield of H-5 
(-position) was observed at pD <5. Since in 18 no 
appreciable shift of that hydrogen was evident, the shift of 
H-5 in5 can be imputed to the base protonation. This fact 
is confirmed by a slight upfield of C-5 [panel (a), Figure 3]. 
  
  
Figure 3. 13C NMR chemical shift of: (a) diamino-dC, 5; (b) N-Bz-diamino-
dA, 12; (c) diamino-T, 17; (d) diamino-dU, 18 as a function of pD. 
The potentiometric titrations were carried out in 0.1 M 
Me4NCl aqueous solution at 298 K. In Table 2, the basicity 
constants of 5, 12, 17, and 18 are presented. The 
comparison of the pKa values indicated that the basicity is 
similar for purine and pirimidine nucleosides. In the case of 
3’,5’-diamino-2’,3’,5’-trideoxycytidine a third pKa of 3.67 
appears, corresponding to protonation at the exocyclic 
amino base, in addition to the pKas for protonation at N-3’ 
and N-5’. 
From the ionization constants the distributions of the 
protonated species of the diaminonucleoside derivatives 
formed as a function of pH were calculated using the 
computer program SUPERQUAD
12
 (Figure 4). The free 
amine predominates at pH >10 whereas at a pH of ca. 7.5-
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8.5 the main species in solution is the monoprotonated 
form. Below pH 5, the diprotonated form exists for dA, T, 
and dU derivatives [(b), (c), and (d), Figure 4] almost 
exclusively. This is also the main species at pH= 4.5-6 in 
3’,5’-diamino-dC (5), which predominates in its fully 
protonated form (LH3
+
) at pH <3 [(a), Figure 4]. 
Table 2. Logarithms of the Protonation Constants of 5, 12, 17, and 18. 
 log K 
reactiona 5 12 17 18 
L+H=HL 8.74 (7)b 9.21 (4) 8.99 (3) 9.06 (5) 
HL+H=H2L 6.49 (7) 6.57 (4) 6.59 (3) 6.78 (5) 
H2L+H=H3L 3.67 (7)    
a Charges have been omitted for clarity. b Values in 
parentheses are standard deviation in the last significant 
figure. 
The distribution of protonated species at different pHs can 
be used as a guide to chemical reactivity. Thus, when we 
carried out the enzymatic acylation of 3’,5’-
diaminothymidine (17), a poor yield of acylated derivative 
was obtained. However, if the process was performed in the 
presence of molecular sieves, the isolated yield of 5’-
acetylnucleoside was increased up to 80%.
8
 To explain this 
fact, a measurement of pH to a water solution of 17 before 
and after the addition of molecular sieves (1:1 w:w) was 
carried out. We observed a slight increase of pH from 8.8 
to 9.2, in which at least 50% of free amine was present. The 
addition of molecular sieves to the enzymatic acylation 
reaction shifts the equilibrium toward the free amine, and 
this favors the above process. The acid-base effects of 
molecular sieves are previously reported in the literature.
13 
In summary, efficient syntheses of 3’,5’-diamino 
derivatives of 2’-deoxycytidine and 2’-deoxyadenosine 
have been described. The sequence of the protonation sites 
and the ionization constants of a series of four 
diaminonucleoside derivatives has been determined by 
potentiometric study and analysis of 
1
H and 
13
C NMR at 
different pD values. The first protonation takes place 
mainly at the 5’-amino group, giving the monoprotonated 
form as the predominant species at ca. pH 8. The 
diprotonated species is present mainly at pH= 5. In the case 
of 3’,5’-diaminocytidine, the base protonation occurs at pH 
values below 3. The distribution diagrams of protonated 
species allows us to determine the predominant form at 
different pHs to plan the best way to perform a process. 
Aminonucleosides 5, 12, 16, and 17 are subjected to 
biological assays and under investigation as monomers for 
antisensse oliogonucleotides. 
 
 
 
 
 
Figure 4. Distribution diagram of protonated especies of:  (a) diamino-dC, 
5 (= L) ; (b) N-Bz-diamino-dA, 12 (= L) ; (c) diamino-T, 17 (= L) ; (d) 
diamino-dU, 18 (= L) as a function of pH. 
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3. Experimental Section 
Melting points were taken on samples in open capillary 
tubes and are uncorrected. IR spectra were recorded on an 
Infrared Fourier Transform spectrophotometer using KBr 
pellets. Flash chromatography was performed using silica 
gel 60 (230-400 mesh). 
1
H-, 
13
C-NMR, and DEPT were 
obtained using AC-200 (
1
H, 200.13 MHz and 
13
C, 50.3 
MHz), and AC-300 (
1
H, 300.13 MHz and 
13
C, 75.5 MHz), 
or DPX-300 (
1
H, 300.13 MHz and 
13
C, 75.5 MHz) 
spectrometers for routine experiments. An AMX-400 
spectrometer operating at 400.13 and 100.61 MHz for 
1
H 
and 
13
C, respectively, was used for the acquisition of 
1
H-
1
H 
and 
1
H-
13
C correlation experiments. The chemical shifts are 
given in delta () values and the coupling constants (J) in 
Hertz (Hz). ESI
+
 was used to record mass spectra (MS). 
Microanalyses were performed on a Perkin-Elmer model 
2400 instrument. For the NMR titrations, the samples were 
prepared with known amounts of the diaminonucleoside, 
the pD was adjusted by addition of DCl or NaOD solutions 
in D2O and the correction pD= pH*+0.4 was used, where 
pH* is the direct measurement of a pH-meter calibrated 
with non-deuterated buffer solutions. For the pH-metric 
titrations, a Metrohm TITROPROCESSOR-636 titrimeter 
was used, the reference electrode was an Ag/AgCl 
electrode in sat. aq. KCl, the cell was thermostated at 
2980.1 K, and the measurements were performed under 
nitrogen atmosphere. The protonation constants were 
determined by titration with 0.1N NaOH of a solution 
containing 10
-3 
M of the HCl salt of the diamine in the 
presence of Me4NCl (0.1 M). The measurements were 
carried out twice, and the data analysis was performed with 
the computer program SUPERQUAD.
12
 
3’,5’-Diazido-4-(1,2,4-triazol-1-yl)-2’,3’,5’-
trideoxycytidine (3).  POCl3 (293 L, 3.15 mmol) was 
added to a suspension of 1,2,4-triazole (1.7 g, 25.16 mmol) 
in dry acetonitrile (21 mL). Triethylamine (3.86 mL, 27.68 
mmol) and a solution of 2
8 
(350 mg, 1.26 mmol) in 4 mL of 
dry acetonitrile were added at 0 ºC. Then, the reaction was 
stirred for 1 h at room temperature. After that, 2.4 mL of 
Et3N and 0.7 mL of water were added and stirred for 10 
min. Later, the solvent was evaporated in vacuo and the 
crude residue was redissolved in a saturated solution of 
NaHCO3 and extracted with CHCl3 (315 mL). The 
organic layer was dried with Na2SO4, filtered off and the 
solvent was evaporated under reduced pressure, affording 
384 mg (93%) of an hygroscopic solid corresponding to 
compound 3.  Rf (EtOAc): 0.54;  IR (KBr):    3235, 3065, 
2932, 2105, 1637, and 1616 cm
-1
;  
1
H-NMR (CDCl3, 200 
MHz):    2.46 (m, 1H, H2’), 2.77 (m, 1H, H2’), 3.67-3.96 
(m, 2H, H5’), 4.07 (m, 1H, H4’), 4.18 (m, 1H, H3’), 6.15 (dd, 
1H, H1’, 
3
JHH 6.7, 
3
JHH 4.9 Hz), 7.12 (d, 1H, H5, 
3
JHH 7.2 
Hz), 8.12 (s, 1H), 8.38 (d, 1H, H6, 
3
JHH 7.2 Hz), and 9.25 (s, 
1H);  
13
C-NMR (CDCl3, 75.5 MHz):    38.5 (C2’), 51.1 
(C5’), 59.2 (C3’), 82.6 (C4’), 87.3 (C1’), 94.7 (C5), 143.1 
(CH), 145.9 (C6), 153.9 (2C, C2+CH), and 159.3 (C4);  MS 
(ESI
+
, m/z):  368 [(M+K)
+
, 4%] and 352 [(M+Na)
+
, 100];  
Anal. Calcd. (%) for C11H11N11O2: C, 40.11; H, 3.37; N, 
46.80. Found: C, 39.9; H, 3.5; N, 46.6. 
3’,5’-Diazido-2’,3’,5’-trideoxycytidine (4). A solution of 
3 (860 mg, 2.61 mmol) in dry 1,4-dioxane (50 mL) was 
cooled at 0 ºC under nitrogen, and then an aqueous solution 
of NH3 (33%, 15 mL) was added. After reaction for 2 h at 
room temperature, the solvent was evaporated in vacuo and 
the crude residue was purified by flash chromatography 
column (gradient eluent 10% to 15% MeOH/EtOAc) 
affording 640 mg (89%) of a white solid corresponding to 
compound 4.  Rf (20% MeOH/EtOAc): 0.28;  Mp: 138-141 
°C;  IR (KBr):    3479, 3414, 3236, 2105, 1637, 1617, 
1483, and 1277 cm
-1
;  
1
H-NMR (MeOH-d4, 300 MHz):    
2.53-2.72 (m, 1H, H2’), 3.79-3.93 (m, 2H, H5’), 4.18 (m, 
1H, H4’), 4.50 (m, 1H, H3’), 6.12 (d, 1H, H5, 
3
JHH 7.4 Hz), 
6.35 (dd, 1H, H1’, 
3
JHH 6.3 Hz), and 7.94 (d, 1H, H6, 
3
JHH 
7.4 Hz);  
13
C-NMR (MeOH-d4, 75.5 MHz):    38.3 (C2’), 
53.1 (C5’), 62.3 (C3’), 83.8 (C4’), 87.4 (C1’), 96.4 (C5), 142.4 
(C6), 158.0 (C2), and 167.7 (C4);  MS (ESI+, m/z): 316 
[(M+K)
+
, 11%], 300 [(M+Na)
+
, 100], and 278 [(M+H)
+
, 
32];  Anal. Calcd. (%) for C9H11N9O2: C, 38.97; H, 4.00; N, 
46.48. Found: C, 39.2; H, 4.1; N, 46.3. 
3’,5’-Diamino-2’,3’,5’-trideoxycitydine (5).  A solution of 
compound 4 (100 mg, 0.36 mmol) in EtOH (6 mL) was 
exposed to a positive pressure of hydrogen gas (balloon) at 
room temperature for 4 h in the presence of 10% palladium 
on charcoal (20 mg). The catalyst was removed by filtration 
on Celite and the filtrate was evaporated to dryness. The 
crude was purified by flash chromatography column [4% 
NH3(aq.)/MeOH] to afford after vacuum drying 58 mg 
(71%) of a white solid corresponding to compound 5.  Rf  
[10% NH3(aq.)/MeOH]: 0.39;  Mp: 186-187 °C 
(decomposed);  IR (KBr):    3550, 3480, 3413, 3239, 
1638, 1617, and 1490 cm
-1
;  
1
H-NMR (D2O, 200 MHz):    
2.04-2.29 (m, 1H, H2’), 2.72-2.98 (m, 2H, H5’), 3.24 (m, 
1H, H4’), 3.66 (m, 1H, H3’), 5.87 (d, 1H, H5, 
3
JHH 7.6 Hz), 
6.01 (dd, 1H, H1’, 
3
JHH 7.0, 
3
JHH 5.0 Hz), and 7.53 (d, 1H, 
H6, 
3
JHH 7.6 Hz);  
13
C-NMR (D2O, 75.5 MHz):    39.5 
(C2’), 42.3 (C5’), 51.7 (C3’), 85.7 (C4’), 86.2 (C1’), 96.1 (C5), 
141.8 (C6), 157.6 (C2), and 166.2 (C4);  MS (ESI
+
, m/z):  
264 [(M+K)
+
, 25%], 248 [(M+Na)
+
, 33], and 226 [(M+H)
+
, 
100];  Anal. Calcd. (%) for C9H15N5O2: C, 47.97; H, 6.72; 
N, 31.10. Found: C, 47.8; H, 6.7; N, 31.1. 
N
6
-Benzoyl-5’-O-(4,4’-dimethoxytrityl)-3’-O-(p-
nitrobenzoyl)-2’-deoxyxyloadenosine (7).14 p-
Nitrobenzoic acid (254 mg, 1.52 mmol) was added to a 
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solution of 6 (500mg, 0.76 mmol) in dry THF (50 mL) 
under nitrogen. Then, Ph3P (400 mg, 1.52 mmol) and 
DEAD (237 L, 1.52 mmol) were added. After reaction for 
2 h at room temperature, the solvent was evaporated in 
vacuo and the crude residue was purified by flash 
chromatography column (EtOAc) affording 432 mg (70%) 
of a yellow solid corresponding to compound 7.  Rf 
(EtOAc): 0.68;  Mp: 109-111 °C;  IR (KBr):    3413, 
2929, 1731, 1638, 1617, 1507, and 1249 cm
-1
;  
1
H-NMR 
(CDCl3, 200 MHz):    3.07 (m, 2H, H2’), 3.46 (dd, 1H, H5’, 
2
JHH 9.0, 
3
JHH 7.4 Hz), 3.69 (dd, 1H, H5’, 
2
JHH 9.0, 
3
JHH 7.4 
Hz), 3.74 (s, 3H, MeO), 3.75 (s, 3H, MeO), 4.67 (m, 1H, 
H4’), 5.96 (m, 1H, H3’), 6.55 (dd, 1H, H1’, 
3
JHH 5.4 Hz), 6.71 
(m, 4H, Hm’), 7.18-7.28 (m, 7H, Ho’+Hm’’+Hp’’), 7.35 (m, 
2H, Ho’’), 7.48-7.67 (m, 5H, Hm+Hp+Ho’’’), 8.01 (m, 2H, 
Ho), 8.20 (m, 3H, H8+Hm’’’), 8.61 (s, 1H, H2), and 9.01 (s, 
1H, NH);  
13
C-NMR (CDCl3, 75.5 MHz):    38.5 (C2’), 
54.6 (2C, 2MeO), 60.2 (C5’), 72.9 (C3’), 82.0 (C4’), 84.0 
(C1’), 86.0 (Ct), 112.5 (Cm’), 123.1 (2C, C5+Cm’’’), 126.4 
(CH), 127.3 (CH), 128.3 (CH), 129.4 (CH), 129.5 (CH), 
129.9 (CH), 132.4 (Cp), 132.8 (C), 133.5 (C), 134.4 (C), 
134.7 (C), 140.2 (C8), 143.6 (Ci’’), 148.9 (C), 150.0 (C), 
150.8 (C), 151.9 (C2), 157.9 (Cp’), 162.7 (Ce), and 164.1 
(Ca);  MS (ESI
+
, m/z):  845 [(M+K)
+
, 37%], 829 [(M+Na)
+
, 
33], and 807 [(M+H)
+
, 100];  Anal. Calcd. (%) for 
C45H38N6O9: C, 66.98; H, 4.75; N, 10.42. Found: C, 67.0; 
H, 4.6; N, 10.2. 
N
6
-Benzoyl-5’-O-(4,4’-dimethoxytrityl)-2’-
deoxyxyloadenosine (8).
15
  Compound 7 (360 mg, 0.45 
mmol) was dissolved in dry MeOH (50 mL) under 
nitrogen, and was cooled at 0 ºC. Then, a solution 0.2 M of 
NaOMe in MeOH (1.8 mL, 0.36 mmol) was added. After 
reaction for 1.5 h at 0 ºC, the solvent was evaporated in 
vacuo and the crude residue was purified by flash 
chromatography column (gradient eluent EtOAc-50% 
MeOH/EtOAc) affording 284 mg (97%) of a white solid 
corresponding to compound 8. 
N
6
-Benzoyl-2’-deoxyxyloadenosine (9).7c  A catalytic 
amount of formic acid (3-4 drops) was added to a solution 
of compound 8 (133 mg, 0.20 mmol) in CHCl3 (14 mL). 
The reaction was stirred for 24 h at room temperature. 
Then, a few drops of 1N KOH were added, the solvent was 
evaporated in vacuo, and the crude residue was purified by 
flash chromatography (gradient eluent 10% to 20% 
MeOH/EtOAc) affording 70 mg (94%) of a white solid 
corresponding to compound 9. 
N
6
-Benzoyl-3’,5’-di-O-methanesulfonyl-2’-
deoxyxyloadenosine (10).  DMAP (688 mg, 5.63 mmol) 
was added to a solution of compound 9 (200 mg, 0.56 
mmol) in dry pyridine (8 mL) under N2. Then, dry 
methanesulphonyl chloride (261 L, 3.38 mmol) was 
added. After reaction for 2 h at room temperature, the 
solvent was evaporated in vacuo, and the crude residue was 
purified by flash chromatography (8% MeOH/EtOAc) to 
afford 216 mg (75%) of a white solid corresponding to 
compound 10.  Rf (20% MeOH/EtOAc): 0.65;  Mp: 75-77 
°C;  IR (KBr):    3494, 1602, 1566, and 1251 cm
-1
;  
1
H-
NMR (MeOH-d4, 200 MHz):    3.18-3.35 (m, 8H, 
H2’+MeS), 4.82 (s, 3H, H5’+H4’), 5.74 (m, 1H, H3’), 6.83 
(dd, 1H, H1’, 
3
JHH 7.1, 
3
JHH 3.0 Hz), 7.71-7.85 (m, 3H, 
Hm+Hp), 8.28 (m, 2H, Ho), 8.78 (s, 1H, H8), and 8.91 (s, 
1H, H2);  
13
C-NMR (MeOH-d4, 50.3 MHz):    37.4 (MeS), 
38.3 (MeS), 40.2 (C2’), 68.3 (C5’), 80.0 (CH), 81.8 (CH), 
85.4 (C1’), 125.1 (C5), 129.4 (CH), 129.8 (CH), 133.9 (Cp), 
134.9 (Ci), 143.4 (C8), 151.1 (C6), 153.1 (C4), 153.3 (C2), 
and 168.1 (C=O);  MS (ESI
+
, m/z):  512 [(M+H)
+
, 100%];  
Anal. Calcd. (%) for C19H21N5O8S2: C, 44.61; H, 4.14; N, 
13.70. Found: C, 44.6; H, 4.2; N, 13.4. 
N
6
-Benzoyl-3’,5’-diazido-2’,3’,5’-trideoxyadenosine 
(11).
7c
  Sodium azide (382 mg, 5.87 mmol) was added to a 
solution of compound 10 (500 mg, 0.98 mmol) in dry DMF 
(15 mL) under nitrogen. The reaction was stirred for 5 h at 
65 ºC, then 2 mL of water were added, and the solvent was 
evaporated in vacuo. The crude residue was purified by 
flash chromatography (EtOAc) affording 297 mg (75%) of 
a white solid corresponding to compound 11. 
N
6
-Benzoyl-3’,5’-diamino-2’,3’,5’-trideoxyadenosine 
(12).
16
  A solution of compound 11 (50 mg, 0.12 mmol) in 
EtOH (4 mL) was exposed to a positive pressure of 
hydrogen gas (balloon) at room temperature for 4 h in the 
presence of Pd black (20 mg). The catalyst was removed by 
filtration on Celite and the filtrate was evaporated to 
dryness. The crude was purified by flash chromatography 
[1% NH3(aq.)/MeOH] to afford after vacuum drying 35 mg 
(81%) of a white solid corresponding to compound 12.  Rf 
[5% NH3(aq.)/MeOH]: 0.33;  Mp: 74-76 °C (decomposed);  
IR (KBr):    3454, 3364, 2936, 1636, 1603, 1567, and 
1488 cm
-1
;  
1
H-NMR (D2O, 300 MHz):    2.32 (m, 1H, 
H2’), 2.64 (m, 1H, H2’), 2.90-3.09 (m, 2H, H5’), 3.54 (m, 
1H, H3’), 3.86 (m, 1H, H4’), 6.23 (dd, 1H, H1’, 
3
JHH 5.7 Hz), 
7. (m, 2H, Hm), 7.36 (m, 1H, Hp), 7.61 (d, 2H, Ho, 
3
JHH 7.7 
Hz), 8.22 (s, 1H, H8), and 8.35 (s, 1H, H2);  
13
C-NMR 
(D2O, 75.5 MHz):    39.4 (C2’), 42.6 (C5’), 52.4 (C3’), 84.6 
(C4’), 85.8 (C1’), 123.7 (C5), 128.2 (CH), 128.9 (CH), 132.7 
(Ci), 133.4 (Cp), 143.3 (C8), 149.6 (C), 151.2 (C), 152.0 
(C2), and 168.2 (C=O);  MS (ESI
+
, m/z):  376 [(M+Na)
+
, 
5%] and 354 [(M+H)
+
, 100];  Anal. Calcd. (%) for 
C17H19N7O2: C, 57.76; H, 5.42; N, 27.76. Found: C, 57.6; 
H, 5.6; N, 27.9. 
N
6
-Benzoyl-3’,5’-di-O-methanesulfonyl-2’-
deoxyadenosine (15).  The same procedure as the one 
described for 10 yielded 15 (white solid, 97%).  Rf (20% 
MeOH/EtOAc): 0.78;  Mp: 57-59 °C;  IR (KBr):    3470, 
2942, 1699, 1603, 1566, 1356, 1250, and 1175 cm
-1
;  
1
H-
NMR (DMSO-d6, 300 MHz):    2.85 (m, 1H, H2’), 3.17 (s, 
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3H, MeS), 3.24-3.38 (m, 4H, H2’+MeS), 4.52 (s, 3H, 
H5’+H4’), 5.58 (m, 1H, H3’), 6.59 (dd, 1H, H1’, 
3
JHH 7.0 Hz), 
7.54 (m, 2H, Hm), 7.64 (m, 1H, Hp), 8.04 (d, 2H, Ho, 
3
JHH 
7.3 Hz), 8.69 (s, 1H, H8), 8.78 (s, 1H, H2), and 11.26 (s, 
1H, NH);  
13
C-NMR (DMSO-d6, 50.3 MHz):    36.0 (C2’), 
36.8 (MeS), 37.8 (MeS), 68.4 (C5’), 79.9 (CH), 81.5 (CH), 
83.7 (CH), 125.9 (C5), 128.5 (2C, Co+Cm), 132.5 (Cp), 
133.3 (Ci), 143.2 (C8), 150.6 (C6), 151.8 (2C, C4+C2), and 
165.7 (C=O);  MS (ESI
+
, m/z):  512 [(M+H)
+
, 100%], and 
534 [(M+Na)
+
, 5%];  Anal. Calcd. (%) for C19H21N5O8S2: 
C, 44.61; H, 4.14; N, 13.70. Found: C, 44.8; H, 3.9; N, 
13.5. 
Acknowledgments 
This work has been supported by grants from MCYT 
(Spain; Project PPQ-2001-2683) and the Principado de 
Asturias (Spain; Project GE-EXP01-03). S. F. thanks 
MCYT for a personal grant (Ramón y Cajal Program). I. L. 
thanks MCYT (Spain) for a predoctoral fellowship. We 
thank Robin Walker for his revision of the English of the 
manuscript. 
References 
1. (a) Robins, R. K.; Revankar, G. R. In Antiviral Drug 
Development; De Clercq, E.; Walker, R. T., Eds.; Plenum 
Press: New York, 1998; p 11. (b) Nucleosides and 
Nucleotides as Antitumor and Antiviral Agents; Chu, C. K.; 
Baker, D. C., Eds.; Plenum Press: New york, 1993. (c) 
MacCoss, M.; Robins, M. J. In Chemistry of Antitumor 
Agents; Wilman, D. E. V., Ed.; Blackie and Son: U. K., 1990; 
p 261. (d) Robins, R. K.; Kini, G. D. Idem; p 299. (e) 
Chemistry of Nucleosides and Nucleotides; Townsend, L. B., 
Ed.; Plenum Press: New York, 1988. 
2. (a) Ferrero, M.; Gotor, V. Chem. Rev. 2000, 100, 4319-4347. 
(b) Kool, E. T. Chem. Rev. 1997, 97, 1473-1487. 
3. (a) Vince, R.; Hua, M. J. Med. Chem. 1990, 33, 17–21. (b) 
Ozaki, S.; Akiyama, T.; Ike, Y.; Mori, H.; Hoshi, A. Chem. 
Pharm. Bull. 1990, 37, 3405-3417. 
4. (a) Singh, I.; Hecker, W.; Prasad, A. K.; Parmar, V. S.; Seitz 
O. Chem. Commun. 2002, 500-501. (b) Singh, S. K.; Kumar, 
R.; Wengel, J. Org. Chem. 1998, 63, 10035-10039. (c) 
Uhlman, E.; Peyman, A. Chem. Rev. 1990, 90, 543-584.  
5. (a) Suhadolnik, R. J. Nucleosides as Biological Probes, 
Wiley-Interscience: New York, 1979. (b) Suhadolnik, R. J. 
Nucleoside Antibiotics, Wiley-Interscience: New York, 1970.  
6. (a) Robins, M. J.; Zou, R.; Hansske, F.; Wnuk, S. F. Can. J. 
Chem. 1997, 75, 762-767. (b) García-Alles, L. F.; Magdalena, 
J.; Gotor, V. J. Org. Chem. 1996, 61, 6980-6986. (c) Robins, 
M. J.; Hawrelak, S. D.; Hernandez, A. E.; Wnuk, S. F. 
Nucleos. Nucleot. 1992, 11, 821-834. (d) Samano, M. C.; 
Robins, M. J. Tetrahedron Lett. 1989, 30, 2329-2332. (e) 
Herdewijn, P.; Balzarini, J.; Masanori, B.; Pauwels, R.; Van 
Aerschot, A.; Janssen, G.; De Clercq, E. J. Med. Chem. 1988, 
31, 2040–2048. (f) Mengel, R.; Wiedner, H. Chem. Ber. 
1976, 109, 433-443.  
7. (a) Pannecouque, C.; Busson, R.; Balzarini, J.; Claes, P.; De 
Clercq, E.; Herdewijn, P. Tetrahedron 1995, 51, 5369-5380. 
(b) Pannecouque, C.; Van Poppel, K.; Balzarini, J.; Claes, P.; 
De Clercq, E.; Herdewijn, P. Nucleos. Nucleot. 1995, 14, 541-
544. (c) Herdewijn, P.; Balzarini, J.; Pauwels, R.; Janssen, G.; 
Van Aerschot, A.; De Clercq, E. Nucleos. Nucleot. 1989, 8, 
1231-1257. (d) Lin, T.; Zhou, R.-X.; Scanlon, K. J.; 
Brubaker, W. F., Jr; Lee, J. J. S.; Woods, K.; Humphreys, C.; 
Prusoff, W. H. J. Med. Chem. 1986, 29, 681–686. (e) Lin, T.-
S.; Prusoff, W. H. J. Med. Chem. 1978, 21,109-112.  
8. Lavandera, I.; Fernández, S.; Ferrero, M.; Gotor, V. J. Org. 
Chem. 2001, 66, 4079-4082. 
9. Divakar, K. J.; Reese, C. B. J. Chem. Soc., Perkin Trans. 1 
1982, 1171-1176. 
10. (a) Garrett, E. R.; Mehta, P. J. J. Am. Chem. Soc. 1972, 94, 
8532-8541. (b) Zoltewicz, J. A.; Clarck, D. F. J. Org. Chem. 
1972, 37, 1193-1197. (c) Romero, R.; Stein, R.; Cordes, H. 
G.; Cordes, E. H. J. Am. Chem. Soc. 1978, 100, 7620-7624. 
11. H. Gunter, in NMR Spectroscopy: Basic Principles Concepts 
and Applications in Chemistry, John Wiley and Sons, 2nd ed., 
1995. 
12. Gans, P.; Sabatini, A.; Vacca, A. J. Chem. Soc., Dalton 
Trans. 1985, 1195-1200. 
13. Fontes, N.; Partridge, J.; Halling, P. J.; Barreiros, S. 
Biotechnol. Bioeng. 2002, 77, 296-305. 
14. Structure of compound 7 is labelled as follows: 
 
15. Chen, J.-K.; Schultz, R. G.; Lloyd, D. H.; Gryanov, S. M. 
Nucleic Acids Res. 1995, 23, 2661-2668. 
16. Linkletter, B. A.; Szabo, I. E.; Bruice, T. C. Nucleic Acids 
Res. 2001, 29, 2370–2376. 
